Literature DB >> 21847534

Novel Lens culinaris agglutinin-reactive fraction of α-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α-fetoprotein concentrations.

Manabu Morimoto1, Kazushi Numata, Akito Nozaki, Masaaki Kondo, Satoshi Moriya, Masataka Taguri, Satoshi Morita, Miki Konno, Akie Sugo, Eiji Miyajima, Shin Maeda, Katsuaki Tanaka.   

Abstract

BACKGROUND: Lens culinaris agglutinin-reactive fraction of α-fetoprotein (AFP-L3) is a specific marker used to detect hepatocellular carcinoma (HCC). However, its clinical utility is not sufficient in patients with low total AFP concentrations because of limitations in instrument sensitivity. Recent advances have led to the introduction of a highly sensitive AFP-L3% assay (sensitive AFP-L3%), provided by a novel on-chip, liquid-phase binding assay. This cross-sectional study was conducted to evaluate the clinical significance of the sensitive AFP-L3% in determining HCC recurrence in patients with low total AFP concentrations.
METHODS: A total of 370 consecutive patients with HCC were screened within 1-3 months of locoregional treatment, and 215 of the 370 patients showed serum AFP <20 ng/ml. Total AFP, sensitive AFP-L3%, and des-gamma-carboxy prothrombin (DCP) were measured in those 215 patients and HCC recurrence was evaluated by radiological findings. Optimal cutoff values of the markers for detecting HCC recurrence were obtained on the basis of receiver operating characteristic (ROC) curve.
RESULTS: The area under the ROC curve of the total AFP, sensitive AFP-L3%, and DCP in HCC patients with serum AFP <20 ng/ml were 0.638, 0.724, and 0.779, respectively. The diagnostic accuracies of the total AFP, sensitive AFP-L3%, and DCP were 60.9% (cutoff value 5 ng/ml), 67.7% (cutoff value 7%), and 64.6% (cutoff value 40 ng/ml), respectively.
CONCLUSIONS: The new sensitive AFP-L3% assay provides great utility in determining HCC recurrence in patients with low AFP concentrations. Further studies focusing on the combinatorial use of the markers (total AFP, sensitive AFP-L3%, and DCP) are required.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21847534     DOI: 10.1007/s10147-011-0306-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  36 in total

1.  Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America.

Authors:  M J Tong; L M Blatt; V W Kao
Journal:  J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 4.029

2.  Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis.

Authors:  Chiaki Kagebayashi; Isao Yamaguchi; Ayumi Akinaga; Hiromichi Kitano; Kazunori Yokoyama; Masahiro Satomura; Tatsuo Kurosawa; Mitsuo Watanabe; Tomohisa Kawabata; William Chang; Chen Li; Luc Bousse; Henry G Wada; Shinji Satomura
Journal:  Anal Biochem       Date:  2009-02-27       Impact factor: 3.365

3.  Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.

Authors:  Adrian M Di Bisceglie; Richard K Sterling; Raymond T Chung; James E Everhart; Jules L Dienstag; Herbert L Bonkovsky; Elizabeth C Wright; Gregory T Everson; Karen L Lindsay; Anna S F Lok; William M Lee; Timothy R Morgan; Marc G Ghany; David R Gretch
Journal:  J Hepatol       Date:  2005-09       Impact factor: 25.083

4.  Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience).

Authors:  Franco Trevisani; Stefania De Notariis; Gianludovico Rapaccini; Fabio Farinati; Luisa Benvegnù; Marco Zoli; Gian Luca Grazi; Poggio Paolo Del; NolfoMariaAnna Di; Mauro Bernardi
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

5.  Clinical significance of tumor markers in detection of recurrent hepatocellular carcinoma after radiofrequency ablation.

Authors:  Tetsuya Beppu; Kazushi Sugimoto; Katsuya Shiraki; Masahiko Tameda; Satoko Kusagawa; Keiichiro Nojiri; Junichiro Tanaka; Norihiko Yamamoto; Yoshiyuki Takei; Haruyuki Takaki; Junji Uraki; Atsuhiro Nakatsuka; Koichiro Yamakado; Kan Takeda
Journal:  Int J Mol Med       Date:  2010-09       Impact factor: 4.101

6.  Establishment of assay kits for the determination of microheterogeneities of alpha-fetoprotein using lectin-affinity electrophoresis.

Authors:  K Shimizu; T Taniichi; S Satomura; S Matsuura; H Taga; K Taketa
Journal:  Clin Chim Acta       Date:  1993-01-31       Impact factor: 3.786

7.  Electrokinetic analyte transport assay for alpha-fetoprotein immunoassay integrates mixing, reaction and separation on-chip.

Authors:  Tomohisa Kawabata; Henry G Wada; Mitsuo Watanabe; Shinji Satomura
Journal:  Electrophoresis       Date:  2008-04       Impact factor: 3.535

8.  Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.

Authors:  Richard K Sterling; Lennox Jeffers; Fredric Gordon; Alan P Venook; K Rajender Reddy; Shinji Satomura; Futoshi Kanke; Myron E Schwartz; Morris Sherman
Journal:  Clin Gastroenterol Hepatol       Date:  2008-09-17       Impact factor: 11.382

9.  Fucosylation index of alpha-fetoprotein, a possible aid in the early recognition of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Y Aoyagi; A Saitoh; Y Suzuki; K Igarashi; M Oguro; T Yokota; S Mori; T Suda; M Isemura; H Asakura
Journal:  Hepatology       Date:  1993-01       Impact factor: 17.425

10.  Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome.

Authors:  Richard Todd Stravitz; Douglas M Heuman; Nisha Chand; Richard K Sterling; Mitchell L Shiffman; Velimir A Luketic; Arun J Sanyal; Adil Habib; Anastasios A Mihas; Ho-Chong S Giles; Daniel G Maluf; Adrian H Cotterell; Marc P Posner; Robert A Fisher
Journal:  Am J Med       Date:  2008-02       Impact factor: 4.965

View more
  10 in total

1.  Diagnostic Value of Different Phenotype Circulating Tumor Cells in Hepatocellular Carcinoma.

Authors:  Yuan Cheng; Lei Luo; Juqiang Zhang; Mantian Zhou; Yujun Tang; Guolin He; Yishi Lu; Zhong Wang; MingXin Pan
Journal:  J Gastrointest Surg       Date:  2019-02-25       Impact factor: 3.452

2.  Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment.

Authors:  Yasushi Tamura; Takeshi Suda; Shigeki Arii; Michio Sata; Fuminori Moriyasu; Hiroshi Imamura; Seiji Kawasaki; Namiki Izumi; Tadatoshi Takayama; Norihiro Kokudo; Masakazu Yamamoto; Hiroko Iijima; Yutaka Aoyagi
Journal:  Dig Dis Sci       Date:  2013-04-18       Impact factor: 3.199

3.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

4.  Circulating Tumor Cells Undergoing the Epithelial-Mesenchymal Transition: Influence on Prognosis in Cytokeratin 19-Positive Hepatocellular Carcinoma.

Authors:  Qian Zhang; Wanting Xing; Jie Zhang; Junwen Hu; Lunan Qi; Bangde Xiang
Journal:  Onco Targets Ther       Date:  2021-03-02       Impact factor: 4.147

5.  Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death.

Authors:  Kashif Rafiq Zahid; Shiming Han; Fuling Zhou; Umar Raza
Journal:  Cell Oncol (Dordr)       Date:  2018-09-20       Impact factor: 7.051

6.  Hepatocellular Carcinoma: a Comprehensive Review ofzzm321990Biomarkers, Clinical Aspects, and Therapy

Authors:  Nathalia Martines Tunissiolli; Márcia Maria Urbanin Castanhole-Nunes; Patrícia Matos Biselli-Chicote; Érika Cristina Pavarino; Renato Ferreira da Silva; Rita de Cássia Martins Alves da Silva; Eny Maria Goloni-Bertollo
Journal:  Asian Pac J Cancer Prev       Date:  2017-04-01

Review 7.  Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment.

Authors:  Federico Piñero; Melisa Dirchwolf; Mário G Pessôa
Journal:  Cells       Date:  2020-06-01       Impact factor: 6.600

8.  Diagnostic Value of the Combination of Golgi Protein 73 and Alpha-Fetoprotein in Hepatocellular Carcinoma: A Meta-Analysis.

Authors:  Meiyu Dai; Xiaoli Chen; Xuexiang Liu; Zheng Peng; Jie Meng; Shengming Dai
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

9.  Clinical, Epidemiological and Histopathological Aspects in Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation

Authors:  Nathalia Martines Tunissiolli; Márcia Maria Urbanin Castanhole-Nunes; Érika Cristina Pavarino; Renato Ferreira da Silva; Rita de Cássia Martins Alves da Silva; Eny Maria Goloni-Bertollo
Journal:  Asian Pac J Cancer Prev       Date:  2018-10-26

10.  The clinical significance of lipopolysaccharide binding protein in hepatocellular carcinoma.

Authors:  Quan-Yu Cai; Jing-Hua Jiang; Ri-Ming Jin; Guang-Zhi Jin; Ning-Yang Jia
Journal:  Oncol Lett       Date:  2019-11-19       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.